Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OLIMEL and PeriOLIMEL are a range of triple-chamber bags for parenteral nutrition developed by Baxter. These products provide a complete nutritional regimen for adult patients who cannot receive adequate nutrition through oral or enteral routes. Each bag contains three separate compartments: one with a solution of L-series amino acids (with or without electrolytes), one with a glucose (dextrose) solution, and one with a lipid emulsion. The lipid component is a unique 80:20 mixture of refined olive oil and refined soybean oil, providing a high content of monounsaturated fatty acids and essential polyunsaturated fatty acids. OLIMEL formulations are designed for central venous administration due to their high osmolarity, while PeriOLIMEL is formulated with a lower osmolarity suitable for peripheral or central venous infusion. They are used to maintain nitrogen and energy balance and to prevent essential fatty acid deficiency in patients with conditions such as postsurgical fasting or severe malnutrition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OLIMEL + PeriOLIMEL.